Home / Biotechnology / High Conte

High Content Screening Market By Product (Instruments, Consumables, Software, Services, Accessories), By Application (Target Identification And Validation, Primary Screening And Secondary Screening, Toxicity Studies, Compound Profiling) - Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Global High Content Screening Market by Products (Instruments, Consumables, Software, Services and Accessories) by Applications (Target Identification and Validation, Primary Screening and Secondary Screening, Toxicity Studies, Compound Profiling and Others) - Market Growth, Future Prospects & Competitive Analysis, 2017 – 2025

High content screening is the most established approach for the multi parametric analysis of cellular events for e.g. the citation 5 cell imaging multi-mode reader combines the automated digital wide field microscopy with conventional multimode microplate reading and can capture the qualitative information regarding the phenotypic cellular information in a single experiment. It has undergone tremendous technological advancements overt the last decade, HCS imaging systems is expected to evolve continuously throughout the forecast period to offer greater flexibility and requirement of assays involving complex cellular disease models. High content screening has rising demands for the analysis of 3D spheroids/microtissues and phenotypic assays, it will have a huge impact in the near future in gene editing studies based on CRISP-Cas9.

For the purpose of this study, the various products studied includes instruments, consumables, software, services and accessories. The applications are classified as target identification and validation, primary screening and secondary screening, toxicity studies, compound profiling and others. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global high content screening market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global high content screening market. Competition assessment tools such as Porter’s five forces analysis, market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global high content screening market. The key players profiled in this report are Becton Dickinson and Company, Bio-Rad Laboratories, BioTek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore Corporation, Olympus Corporation, Perkin Elmer, Inc., Tecan Group and Yokogawa Electric Corporation.

High Content Screening Market

Based on application, the global high content screening market is categorized into

  • Target Identification and Validation
  • Primary Screening and Secondary Screening
  • Toxicity Studies
  • Compound Profiling
  • Others

High Content Screening Market

The high content screening is witnessing tremendous growth significantly due to increasing need to launch novel drug molecules owing to the presence of outdated drug therapy regimen with ineffective pharmacodynamic profile. Additionally the burgeoning requirement to promote intensive treatment of chronic diseases such as cardiovascular complications, diabetes, Alzheimer’s, Parkinson’s, cancer, etc. Drug toxicity screening is necessary for new drug application (NDA) and clinical trial approval before the drug enters the market. In 2016, target identification and validation and primary and secondary screening both dominated the market mainly due to factors such as increasing number of biosimilars and biological drug candidates in the market requiring primary and secondary screening to prove drug efficacy and safety. Additionally the Hope Act (2013) signed by US government to encourage the development of novel therapies for children with rare diseases will employ target identification and validation to determine the approach for drug discovery and development.  The toxicity studies segment is anticipated to register faster growth throughout the forecast period 2017-2025, majorly due to rising incidence of drug related adverse events, increased risk associated with the toxic metabolites produced by the drug biotransformation process, and stringent regulatory norms by USFDA to enhance the drug toxicity screening in the drug clinical trial phase.

For the purpose of this study, the global high content screening market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

 High Content Screening Market

North America was observed to be the largest market for high content screening in the base year 2016. The dominance of North America is mainly attributed to the presence of key pharmaceutical players focusing on novel drug discovery and enhanced government spending in the research and development facilities in healthcare institutions. The market growth in Europe is mainly attributed to the increasing number of patients suffering with rare diseases such as Gaucher disease, Pompe disease or multiple sclerosis. This factor boosts the demand for phenotypic drug screening and technological advancement in the instruments employed for image analysis and data collection for cellular activities. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are presence of large patient pool which can be enrolled to study drug toxicity studies for drug clinical trials, competitive market due to presence of existing major players and evolving biopharmaceutical and medical imaging manufacturers in these regions, and supportive regulatory environment for high content screening products. Moreover, factors such as developing health infrastructure, public private partnership between major pharma players and government agencies are going to fuel the rapid growth of high content screening market in Latin America, and Middle East and Africa region in the near future.   

Choose License Type
Published Date:  Aug 2017
Category:  Biotechnology
Report ID:   58619
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Connect With Us
+1-408-641-3282
24/7 Research Support